Maybe we could be better than Neuren -Neu, page-10

Thanks for the reply. When I was writing the post previously I was thinking SOI was smaller than it is (just calculated). I know SOI's is important if comparing companies and sp movement etc.

I tend to side with Glory, though I respect your view point. I don't see FDA as irrelevant as you suggest but understand it's not cheap or easy and it's not going to happen overnight. The conditions that NTI are working with have very few, if any at all, treatments available globally. If NTI can have successful trials with a safe and effective drug and improve the lives of sufferers etc, then this drug won't just be used in Aus. How that transpires through possible partnerships etc is yet to be seen. I don't necessarily see NTI getting to $23 like NEU but I think there is still plenty of upside in this stock.

Will be an interesting and possibly exciting year for holders and hopefully even more exciting for patients and their families.